{
  "abstract": "Objectives Anifrolumab is a biologic recently approved for systemic lupus erythematosus (SLE), with efficacy shown in trials, but data from real-world practice remain limited. The aim of this registry is to evaluate the effectiveness and safety of anifrolumab in SLE patients under real-life routine care in Spanish rheumatology centers.Methods Multicenter, ambispective study including SLE patients (2019 EULAR/ACR criteria), treated with anifrolumab and followed up to 6m. Clinical, labs, and treatment data were collected. Disease activity (SLEDAI-2k, SLE-DAS, PGA), damage (SLICC/ACR/DI), remission (DORIS-21), low disease activity (LLDAS), Comparisons across visits were done using Friedman’s test (adjusted by Holm’s method) and Cochran’s Q with McNemar’s test (Bonferroni correction) for binary outcomes.Results Among 133 patients, 100 completed the 3-month visit and 82 the 6-month visit. Median age was 49 years (IQR ±17), 87.9% were female. Significant improvements at 3 and 6m compared with the baseline were observed in SLEDAI, SLEDAS, PGA, percentage of patients in remission DORIS-21 and in LLDAS, and the number of patients receiving glucocorticoids (GC) at 6m ( figures 1 and 2). Flares significantly dropped from 2 (±2) at baseline to 0 (±0 at 3m and ±1 at 6m). Response rates were: physician’s criteria 77.1% at 3m and 75.7% at 6m; 50% response in 63.5% and 65.1%; 20% response in 83.6% and 74.5%; serological response in 41.3% and 34.9% (all p = not significant) (figure 2). There were no differences in either SDI at baseline vs. 6m (0 ± 1 vs. 0 ± 1), or anti-dsDNA titers or GC dosages among any of the 3 visits. Number of csDMARDS was reduced substantially (figure 1).Discontinuation occurred in 5/95 patients (5%) before 3m and 10/72 (12.2%) between 3–6m. Five (3.8%) patients presented a COVID-19 and 4 (3%) a herpes zoster. None of the patients died. Two patients were hospitalized due to serious infections and 3 to both SLE activity and infection.Abstract PO:11:281 Figure 1–2Conclusions 1° In real-life clinical setting, anifrolumab improved multiple SLE activity measures at 3 and 6 months, with a substantial proportion of patients achieving early LLDAS or DORIS-Remission, along with reduced flare rates and glucocorticoids use; 2° No new security alarms have appeared.",
  "authors": [
    {
      "affiliations": [
        "Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas GC, Spain"
      ],
      "name": "Iñigo Rua-Figueroa"
    },
    {
      "affiliations": [
        "Hospital del Mar, Barcelona, Spain"
      ],
      "name": "Tarek Carlos Salman-Monte"
    },
    {
      "affiliations": [
        "Hospital del Mar, Barcelona, Spain"
      ],
      "name": "Laura Triginer"
    },
    {
      "affiliations": [
        "Hospital Germans Trias i Pujol, Barcelona, Spain"
      ],
      "name": "Judit Font-Urgel"
    },
    {
      "affiliations": [
        "Hospital Universitario Ramón y Cajal, Madrid, Spain"
      ],
      "name": "Sandra Garrote Corral"
    },
    {
      "affiliations": [
        "Hospital Universitario 12 de octubre, Madrid, Spain"
      ],
      "name": "Carlos De Frías Polo"
    },
    {
      "affiliations": [
        "Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"
      ],
      "name": "Berta Magallares"
    },
    {
      "affiliations": [
        "Hospital General Universitario de Valencia, Valencia, Spain"
      ],
      "name": "Jorge Juan Fragio Gil"
    },
    {
      "affiliations": [
        "Hospital Universitario Vall Hebron, Barcelona, Spain"
      ],
      "name": "Josefina Cortés"
    },
    {
      "affiliations": [
        "Complejo Asistencial Universitario de León, León, Spain"
      ],
      "name": "Clara Moriano Morales"
    },
    {
      "affiliations": [
        "Hospital General Universitario de Alicante, Alicante, Spain"
      ],
      "name": "Pilar Bernabeu"
    },
    {
      "affiliations": [
        "Hospital Meixoeiro, Vigo, Spain"
      ],
      "name": "Irene Altabás-González"
    },
    {
      "affiliations": [
        "Hospital Son Llàtzer, Palma de Mallorca, Spain"
      ],
      "name": "Samuel Hernández Baldizón"
    },
    {
      "affiliations": [
        "Hospital Universitario Virgen de Valme, Sevilla, Spain"
      ],
      "name": "Consuelo Ramos Giráldez"
    },
    {
      "affiliations": [
        "Hospital Sierrallana, Torrelavega, Spain"
      ],
      "name": "Leyre Riancho-Zarrabeitia"
    },
    {
      "affiliations": [
        "Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain"
      ],
      "name": "María Piqueras García"
    },
    {
      "affiliations": [
        "Hospital Universitario de Toledo, Toledo, Spain"
      ],
      "name": "Ángel María García-Aparicio"
    },
    {
      "affiliations": [
        "Hospital de Sagunto, Valencia, Spain"
      ],
      "name": "Marta Garijo Bufort"
    },
    {
      "affiliations": [
        "Hospital Clínic, Barcelona, Spain"
      ],
      "name": "Beatriz Frade Sosa"
    },
    {
      "affiliations": [
        "Consorci Coporació Sanitaria Parc Taulí, Sabadell, Spain"
      ],
      "name": "Silvia García Cirera"
    },
    {
      "affiliations": [
        "Hospital Comarcal Alt Penedès-Garraf (CSAPG), Vilafranca del Penedès, Spain"
      ],
      "name": "Vicenç Torrente Segarra"
    },
    {
      "affiliations": [
        "Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas GC, Spain"
      ],
      "name": "Andrea Hernández-Martín"
    },
    {
      "affiliations": [
        "Hospital Meixoeiro, Vigo, Spain"
      ],
      "name": "José María Pego-Reigosa"
    },
    {
      "affiliations": [
        "Hospital del Mar, Barcelona, Spain"
      ],
      "name": "Irene Carrión-Barberà"
    }
  ],
  "title": "PO:11:281 Spanish real-world ambispective multicenter registry of anifrolumab in systemic lupus erythematosus: efficacy and safety at 3- and 6-month follow-up (ANIFRO-reu study)",
  "uid": "e48a9a3b-447e-5e1b-862f-afe990fe3bc1"
}